---
title: "Beam Therapeutics Inc. (BEAM.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BEAM.US.md"
symbol: "BEAM.US"
name: "Beam Therapeutics Inc."
industry: "Biotechnology"
datetime: "2026-05-20T19:14:29.704Z"
locales:
  - [en](https://longbridge.com/en/quote/BEAM.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BEAM.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BEAM.US.md)
---

# Beam Therapeutics Inc. (BEAM.US)

## Company Overview

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [beamtx.com](https://beamtx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: B (0.37)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 30 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 157.97% |  |
| Net Profit YoY | 82.92% |  |
| P/B Ratio | 2.32 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2705294096.69 |  |
| Revenue | 164011000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -5.77% | D |
| Profit Margin | -40.23% | E |
| Gross Margin | 65.16% | A |
| Revenue YoY | 157.97% | A |
| Net Profit YoY | 82.92% | A |
| Total Assets YoY | 0.95% | C |
| Net Assets YoY | 3.68% | C |
| Cash Flow Margin | 560.37% | A |
| OCF YoY | 157.97% | A |
| Turnover | 0.11 | E |
| Gearing Ratio | 21.36% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Beam Therapeutics Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "157.97%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "82.92%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.32",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2705294096.69",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "164011000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "-5.77%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-40.23%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "65.16%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "157.97%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "82.92%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.95%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "3.68%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "560.37%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "157.97%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.11",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "21.36%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -41.00 | 535/386 | - | - | - |
| PB | 2.32 | 212/386 | 2.78 | 2.26 | 1.66 |
| PS (TTM) | 16.49 | 187/386 | 47.54 | 32.12 | 22.30 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **17**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 14 | 82% |
| Overweight | 1 | 6% |
| Hold | 2 | 12% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 27.11 |
| Highest Target | 80.00 |
| Lowest Target | 26.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BEAM.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BEAM.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BEAM.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BEAM.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**